These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7875148)

  • 21. Meglumine antimoniate-induced pancreatitis.
    Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
    Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
    [No Abstract]   [Full Text] [Related]  

  • 22. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
    Berhe N; Ali A; Hailu A; Yeneneh H
    Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visceral leishmaniasis with cutaneous and rectal dissemination due to Leishmania braziliensis in acquired immunodeficiency syndrome (AIDS).
    Hernández DE; Oliver M; Martínez C; Planas G
    Int J Dermatol; 1995 Feb; 34(2):114-5. PubMed ID: 7737768
    [No Abstract]   [Full Text] [Related]  

  • 26. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
    Segura I; García-Bolao I
    Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
    Laguna F; López-Vélez R; Soriano V; Montilla P; Alvar J; González-Lahoz JM
    J Infect; 1994 May; 28(3):255-9. PubMed ID: 8089514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of infantile visceral leishmaniasis].
    Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
    Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
    Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
    Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of kala azar.
    Ozsoylu S
    Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
    Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
    Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma.
    de Górgolas M; Castrillo JM; Fernández Guerrero ML
    Clin Infect Dis; 1993 Jul; 17(1):56-58. PubMed ID: 8353246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [N-methyl glucamine antimoniate or Glucantime].
    Rapp C; Simon F; Dordain ML
    Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
    [No Abstract]   [Full Text] [Related]  

  • 35. Pediatric visceral leishmaniasis in southern France.
    Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
    Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable.
    de Oliveira-Neto MP; Mattos Mda S
    Rev Soc Bras Med Trop; 2006; 39(4):323-6. PubMed ID: 17119744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
    Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
    Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucantime-resistant visceral leishmaniasis in immunocompromised patients.
    Verdejo J; Alvar J; Polo RM; González-Lahoz JM
    Am J Med; 1988 Jul; 85(1):128. PubMed ID: 3389377
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.